Orchid BioSciences, Inc ORCH Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Orchid BioSciences, Inc ORCH

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (48)	12/21/2001 10:26:46 AM
From: Glenn Petersen	Read Replies (1) of 94

ORCH to beat top line estimates: biz.yahoo.com Friday December 21, 8:09 am Eastern Time Orchid sees 4th-quarter revenues beating forecasts PRINCETON, N.J., Dec 21 (Reuters) - Orchid Biosciences Inc. (NasdaqNM:ORCH - news), a maker of genetics research products, said on Friday it expects fourth-quarter revenues to be about 33 percent higher than Wall Street expectations, citing its acquisition of genomics testing company Lifecodes. Orchid forecast revenues of about $10 million for the quarter, while estimates from two analysts surveyed by Thomson Financial/First Call ranged from $7.3 million to $7.7 million, for an average of $7.5 million. Orchid also said it expects to post a loss of $1.33 to $1.38 a share for the full year. First Call's consensus loss estimate is $1.34, based on forecasts from four analysts. The company said it expects 2001 revenues of $28 million to $30 million, up 50 percent to 60 percent from 2000. For 2002, it sees revenues of more than $55 million. Shares of Orchid closed at $4.30 in Thursday Nasdaq trade, the lower end of a 52-week range of $1.50 to $15.75.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next